8-MOP (methoxsalen hard gelatin capsules) / Bausch Health - LARVOL DELTA

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - P2 | N=15 | Not yet recruiting | Sponsor: London Health Sciences Centre OR Lawson Research Institute of St. Joseph's | Trial primary completion date: Dec 2026 ➔ Jul 2026

Trial primary completion date • Immunology • Scleroderma • Systemic Sclerosis

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - P2 | N=15 | Not yet recruiting | Sponsor: Lawson Health Research Institute | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - P2 | N=15 | Not yet recruiting | Sponsor: Lawson Health Research Institute | Trial completion date: Jun 2024 ➔ Jun 2026 | Trial primary completion date: Sep 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis • CRP

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - P2 | N=15 | Not yet recruiting | Sponsor: Lawson Health Research Institute | Initiation date: Mar 2022 ➔ Sep 2022 | Trial primary completion date: Mar 2023 ➔ Sep 2023

Trial initiation date • Trial primary completion date • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis • CRP

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - P2; N=15; Not yet recruiting; Sponsor: Lawson Health Research Institute; Trial completion date: Mar 2024 ➔ Jun 2024; Initiation date: Sep 2021 ➔ Mar 2022; Trial primary completion date: Sep 2023 ➔ Mar 2023

Trial completion date • Trial initiation date • Trial primary completion date • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis • CRP

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - P2; N=15; Not yet recruiting; Sponsor: Lawson Health Research Institute

New P2 trial • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis • CRP

Clinical efficacy of psoralen+sunlight versus combination of Isotretinoin and psoralen+sunlight for the treatment of chronic plaque-type psoriasis vulgaris : A randomized hospital based study (Photodermatol Photoimmunol Photomed) - P=NA, N=35; "There was a statistically significant difference between the 2 study groups for the number of patients achieving endpoint of PASI 75; PASI scores in each study group at the end of 12 weeks; mean duration to achieve PASI 75; number of sittings of PUVAsol to achieve PASI75; and mean cumulative dosage of 8-MOP consumed by a patient to achieve PASI 75....Combination of isotretinoin with PUVAsol(RePUVAsol) is more effective compared to PUVAsol alone for treating chronic plaque psoriasis."

Clinical data • Psoriasis

SNEV(P) (rp19/) (PSO) (4) deficiency increases PUVA induced senescence in mouse skin. (PubMed) - Exp Dermatol - "In old SNEV(P) (rp19/) (PSO) (4) mice this increase is accompanied by reduced epidermis thickening and increase of p16 and of collagenase levels. Thus, the DNA damage response occurring in the mouse skin upon PUVA treatment is dependent on SNEV(P) (rp19/) (PSO) (4) expression and lower levels of SNEV(P) (rp19/) (PSO) (4) , as in old SNEV(+/-) mice, result in increase of cellular senescence and acceleration of premature skin aging."

Journal • Biosimilar